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LESS ISMORE
Estimating Vitamin D Status and the Choice
of Supplementation Dose
To the Editor In a recent issue of JAMA Internal Medicine,
Bischoff-Ferrari and colleagues1 reported the results of an
interesting randomized clinical trial testing the efficiency of
physiological (equivalence, 800 IU/d) and supraphysiologi-
cal doses (equivalence, 2000 IU/d or 800 IU/d plus calcife-
diol 300 μg/mo) of vitamin D supplements in lowering the
risk of functional decline. The authors found that older par-
ticipants in the higher-dose vitamin D groups experienced
the greater incidence of falls,1 a result already described
with mega doses of vitamin D supplementation2 but in
contradiction with the well-recognized antifall effect of
physiological doses.3
Before claiming that high-dose vitamin D supplementa-
tion makes seniors fall, we wish to draw attention to the
secondary analyses stratified by initial vitamin D status.1
The 12-month number of falls was greater after high-dose
vs low-dose vitamin D supplementation only in the group
that had no hypov i t aminos i s D at base l ine ( i e ,
25-hydroxyvitamin D [25(OH)D] ≥ 20 ng/mL [to convert
25[OH]D level to nanomoles per liter, multiply by 2.496]),
but not in the group with initial hypovitaminosis D less
than 20ng/mL (P = .03 and P = .33, respectively). It thus
appears that, among people without hypovitaminosis D,
high-dose vitamin D supplementation, aimed at increasing
25(OH)D concentration to supraphysiological levels, is
probably not useful—and might be toxic—compared
with lower doses aiming at preventing hypovitaminosis D
and maintaining 25(OH)D concentration to physiological
levels.
These data confirm the current hypothesis of a possible
U-shaped or J-shaped effect of vitamin D, with both low and
high 25(OH)D concentrations being associated with adverse
health events.4 For this reason, we call for the need to deter-
mine older individuals’ vitamin D status before any vitamin
D supplementation. However, we recognize that such sys-
tematic screening for hypovitaminosis D is currently com-
promised in this population due to the cost of 25(OH)D
assay, which is higher than the annual supplementation. To
avoid the current trend toward universal supplementation
on sight, and to help determining which individuals should
receive lower-dose or higher-dose vitamin D supplements,
it is urgently needed to develop new cost-effective routine
screening strategies to provide an appropriate medical
decision. For instance, we recently developed a clinical tool
able to identify older adults with hypovitaminosis D who
may be administered high-dose supplements without blood
test.5 Further investigations will be necessary to examine
the feasibility, cost-effectiveness, and usefulness of such
tools in daily practice and to estimate if they allow supple-
menting older adults in a personalized way, thus avoiding
vitamin D toxic effects described by Bischoff-Ferrari and
colleagues.
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In ReplyWeagree thathigh-dosemonthlyvitaminD isnotnec-
essarily harmful among seniors with vitamin D deficiency.
However, everyone treated with 24 000 IU vitamin D per
month (equivalent to 800 IU/day) achieved the replete range
of above20ng/mL25(OH)D (to convert 25[OH]D level tonano-
moles per liter, multiply by 2.496), with none reaching a
25(OH)D level above45ng/mL.1Thegroup treatedwith24000
IU per month included 59.7% of participants with deficient
25(OH)Dstarting levels less than20ng/mLand40.3%with re-
plete 25(OH)D starting levels greater than 20 ng/mL (range,
20.1-43.5ng/mL). Thus, at starting levels throughout thewide
rangeof4.9 to43.5ng/mL, 24000 IUvitaminDpermonthap-
pears tobeeffective in safelybringing25(OH)D levels intowhat
currently appears tobe thedesirable range for fall prevention.1
Thisdoesnotmean thatmeasuring25(OH)Dstatus isnever in-
dicated but suggests that wide spread assessments by serum
analysis or algorithmmay not be necessary.
Heike A. Bischoff-Ferrari, MD, DrPH
E. John Orav, PhD
Bess Dawson-Hughes, MD
Author Affiliations:Department of Geriatrics and Aging Research, University
Hospital Zurich, Switzerland (Bischoff-Ferrari); Centre on Aging andMobility,
University of Zurich, Switzerland (Bischoff-Ferrari); Department of Biostatistics,
Harvard School of Public Health, Boston, Massachusetts (Orav); USDA Human
Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts
(Dawson-Hughes).
Letters
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine June 2016 Volume 176, Number 6 865
Downloaded From: http://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 12/16/2016
Copyright 2016 American Medical Association. All rights reserved.
Corresponding Author:Heike A. Bischoff-Ferrari, MD, DrPH, Department of
Geriatrics and Aging Research, University Hospital Zurich, Raemistrasse 100,
Zurich, Zurich 8091 (Heike.Bischoff@usz.ch).
Conflict of Interest Disclosures:None reported.
1. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose
vitamin D treatment for the prevention of functional decline: a randomized
clinical trial. JAMA Intern Med. 2016;176(2):175-183.
Adverse Effects of Proton Pump Inhibitors
in Chronic KidneyDisease
To theEditorProtonpumpinhibitors (PPIs) areextensivelyused
for commongastrointestinal disorderswhere the inhibitionof
gastric acid secretion is desirable, such as gastroduodenal ul-
cer, dyspepsia and gastroesophageal reflux disease. Lazarus
et al1 showedanassociationbetweenPPI use and ahigher risk
of incident chronickidneydisease (CKD).Furthermore, theau-
thors touched on PPI induced hypomagnesemia as a possible
mediator of CKD worsening. We agree with and support this
hypothesis, expanding on the possible adverse effects of in-
appropriately prescribed PPIs in patients with CKD. Proton
pump inhibitors interferewith the active transport ofmagne-
sium,andclinically significantphenomenaareobserved in the
carriersofheterozygoticmutationsofTRPM6/7.2Protonpump
inhibitor-associated hypomagnesemia has been highlighted
both in the general population and patients with CKD. We
showed that chronic PPI use is associatedwith increased vas-
cular calcification risk inhemodialysispatients.3Becausemag-
nesium is acting as inhibitor of calcification, it is possible that
PPI-induced hypomagnesemia may worsen vascular calcifi-
cations in patients with CKD.Magnesium is also deposited in
large quantities in bone, being essential for bone health, and
chronic PPI treatment may be associated with clinical spine,
forearm or wrist, and total fractures, although not hip frac-
tures and with only a marginal effect on 3-year bone mineral
density change at the hip.4
There is another potential mechanism justifying the in-
creased risk of CKD progression observed by Lazarus et al.1
Protonpump inhibitor administration increasedplasmaasym-
metric dimethylarginine (ADMA) levels and reduced nitric
oxide levels and endothelium-dependent vasodilation in a
murinemodel and ex vivo in human tissues. Protonpump in-
hibitors increased ADMA because they bind to and inhibit di-
methylarginine dimethylaminohydrolase, the ADMA cata-
bolic enzyme. This observation offers a plausible biological
mechanism to explain the observed association of PPI treat-
ment with increased major adverse cardiovascular events in
patients with acute coronary syndrome,5 but ADMA eleva-
tion may also have a relevant effect on CKD progression. We
suggest that prescription of PPIs for patients with CKD,
heavily exposed to the risk of cardiovascular morbidity and
mortality, should be carefully considered because of their
possible adverse effects on cardiovascular health and bone
health. Proton pump inhibitors are potentially inappropriate
medications in CKD patients.
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To the Editor In an investigation toquantify the associationbe-
tween the use of proton pump inhibitors (PPIs) and incidence
of chronic kidney disease (CKD) in a population-based
cohort, Lazarus et al1 concluded thatPPIuse is associatedwith
a higher risk of CKD. In this sense, we would like to express
concern about thebaseline characteristics of patientswhoare
prescribed PPIs that could constitute an important source of
bias. Indeed, PPIusersweremore likely thannonusers tohave
a greater burden of prescribed medications and comorbidi-
ties that influence the baseline risk of CKD for reasons
unrelated to their PPI use.
In fact, there is supportive evidence that nonsteroidal
anti-inflammatory drug (NSAID) use is associated with
increased risk of CKD in patients with hypertension,2 and a
triple therapy combination of diuretics with angiotensin-
converting-enzyme (ACE) inhibitors or angiotensin receptor
blockers and NSAIDs was associated with an increased risk
of acute kidney injury.3 Moreover, the coexistence of hyper-
tension is associated with more rapid progression of CKD,4
and CKD is frequently the result of hypertension and
diabetes mellitus.5
Thus, under circumstances like the raised and combined
presence of several risk factors (eg, NSAID and ACE inhibitor
use, diagnosis of hypertension, diabetes mellitus) that in-
crease the risk of CKD among PPI users at baseline, the selec-
tion of patients could be biased making the interpretation of
hazard ratio data verydifficult in spite of the stratificationbe-
causetheunderlyinghazardfunctionwouldbedifferentamong
PPI users and patients who do not use PPIs.
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